Pregnancy Hormone May Help Fight HIV

April 02, 1997

An animal study at the National Institutes of Health has produced intriguing evidence that a pregnancy hormone may protect the developing fetus from the ravages of the human immunodeficiency virus, HIV. The study also points to a potential role for the hormone in fighting HIV-related wasting. The hormone in question is human chorionic gonadotropin, abbreviated hCG. Normally produced by the placenta to help maintain pregnancy, hCG is the hormone that produces a positive pregnancy test.

The possible connection between hCG and HIV was studied in a special strain of transgenic mice. The mice had been engineered to contain an incomplete set of HIV genes in the DNA of every cell in their bodies. The virus could not reproduce, but could trick certain mouse cells into making many of the viral proteins. Baby mice that inherit HIV DNA from each transgenic parent eventually accumulate enough viral protein that they develop skin lesions, wasting syndrome, and die within 3 to 6 weeks.

However, when the mice were treated with hCG, the majority of the animals showed normal weight gain as long as they were receiving the hormone. Furthermore, their cells produced considerably less viral protein than animals not receiving hormone treatment, and skin lesions were dramatically reduced. The study appears in the April 2 issue of The Journal of Clinical Investigation.

The results of this study could have implications in treating human HIV infection, according to Dr. Abner Notkins, who directed the research at the National Institute of Dental Research (NIDR). "Human chorionic gonadotropin may be another weapon to use against HIV," said Dr. Notkins. "The hormone may explain the relatively low rate of HIV transmission from mother to infant, and also could have potential for treating HIV-associated wasting syndrome in children and adults."

Dr. Notkins and his colleagues first recognized that maternal hormones might have a protective effect against HIV when they observed that newborn transgenic mice appear normal in size and weight, but soon show marked growth retardation. By 8 days of age they weigh 60 percent less that their normal littermates. It appeared to the investigators that the baby mice were protected by maternal hormones during pregnancy, and became susceptible to the effects of HIV once the level of hormones dropped dramatically at birth.

To test this theory, Dr. Swapan De, lead author on the paper, implanted tiny hormone-containing pumps under the skin of nursing mothers. As a result, the baby mice maintained an elevated level of hormones by way of the mother's milk. At weaning, the young mice continued to receive hormones by injection. In addition to intact hCG, Dr. De and his collaborators also evaluated the effects of the two separate components that make up the molecule, called the alpha and beta subunits. The alpha subunit is common to several closely related hormones, but the beta subunit gives hCG its identity and is the site of its activity. Other hormones tested were estrogen, progesterone, and dexamethasone--a potent synthetic steroid.

Only hCG and its beta subunit reduced the production of HIV proteins and protected the mice from skin lesions and wasting. If treatment was withdrawn, the symptoms appeared and the animals died. The alpha subunit was ineffective, and the other hormones not only failed to protect the mice, but actually accelerated the onset of symptoms.

Scientists still don't know the exact mechanism by which hCG inhibits HIV. However, the NIDR results support test tube studies from other laboratories, which showed that hCG or its beta subunit could lower production of the viral proteins and block cell-to-cell transmission of HIV. The beta subunit has even been shown to kill Kaposi's sarcoma cells in the laboratory and prevent these cells from producing tumors in mice.

Collaborating with Drs. De and Notkins were Mr. Charles R. Wohlenberg, Ms. Nancy J. Marinos, Mr. Davanand Doodnauth, and Dr. Joseph Bryant from the National Institute of Dental Research. NIDR is one of the National Institutes of Health located in Bethesda, Maryland.
-end-


NIH/National Institute of Dental and Craniofacial Research

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.